Comparative Pharmacokinetics of Tixagevimab/Cilgavimab (AZD7442) Administered Intravenously Versus Intramuscularly in Symptomatic SARS‐CoV‐2 Infection is a research paper published in Clinical Pharmacology & Therapeutics (2022). On theSindex it has a DataRank of 1.2. It has been cited 14 times, with 11 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.406
From this paper's citation signal
Citation Network Contribution
0.790
From 8 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 11 citers.
National Institutes of Health
Grant: UM1AI106701
National Institutes of Health
Grant: UM1AI068636
National Institutes of Health
Grant: UM1AI068634
National Institutes of Health
Grant: 3UM1AI068636‐14S2
NIAID NIH HHS
Grant: UM1 AI069424
NIAID NIH HHS
Grant: UM1 AI069481
NIAID NIH HHS
Grant: UM1 AI069423
National Institutes of Health
Grant: 5UM1AI068634-09
Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)
National Institutes of Health
Grant: 3UM1AI068636-14S2
Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/
National Institutes of Health
Grant: 3UM1AI106701-12S1
AIDS Clinical Trial Group Laboratory Center
National Institutes of Health
Grant: 3UM1AI068636-19SC
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
FWCI
1.26
Citation Percentile
0.8%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals